DekaBank Deutsche Girozentrale Has $852,000 Stake in Editas Medicine (EDIT)

DekaBank Deutsche Girozentrale lifted its position in Editas Medicine (NASDAQ:EDIT) by 252.7% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 26,100 shares of the company’s stock after purchasing an additional 18,700 shares during the quarter. DekaBank Deutsche Girozentrale owned 0.06% of Editas Medicine worth $852,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Glenmede Trust Co. NA bought a new stake in shares of Editas Medicine in the 4th quarter worth about $153,000. Martingale Asset Management L P bought a new stake in shares of Editas Medicine in the 4th quarter worth about $219,000. Teacher Retirement System of Texas bought a new stake in shares of Editas Medicine in the 4th quarter worth about $253,000. Rothschild Investment Corp IL bought a new stake in shares of Editas Medicine in the 4th quarter worth about $263,000. Finally, D.A. Davidson & CO. bought a new stake in shares of Editas Medicine in the 4th quarter worth about $267,000. 62.98% of the stock is currently owned by institutional investors and hedge funds.

Shares of NASDAQ EDIT opened at $34.85 on Friday. The company has a current ratio of 11.71, a quick ratio of 11.71 and a debt-to-equity ratio of 0.13. Editas Medicine has a 12-month low of $13.12 and a 12-month high of $45.02.

Editas Medicine (NASDAQ:EDIT) last issued its quarterly earnings results on Thursday, May 3rd. The company reported ($0.67) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.82) by $0.15. The business had revenue of $3.90 million for the quarter, compared to the consensus estimate of $4.04 million. Editas Medicine had a negative net margin of 707.98% and a negative return on equity of 58.73%. The firm’s quarterly revenue was up 473.5% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.85) EPS. research analysts expect that Editas Medicine will post -3 earnings per share for the current year.

In related news, insider Katrine Bosley sold 8,333 shares of the company’s stock in a transaction dated Thursday, March 1st. The shares were sold at an average price of $35.72, for a total transaction of $297,654.76. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Andrew A. F. Hack sold 6,000 shares of the company’s stock in a transaction dated Friday, March 16th. The stock was sold at an average price of $39.43, for a total transaction of $236,580.00. Following the transaction, the chief financial officer now owns 6,000 shares in the company, valued at approximately $236,580. The disclosure for this sale can be found here. In the last quarter, insiders have sold 80,133 shares of company stock worth $3,001,893. 19.40% of the stock is owned by corporate insiders.

Several research firms have recently weighed in on EDIT. BidaskClub raised shares of Editas Medicine from a “hold” rating to a “buy” rating in a report on Friday. ValuEngine raised shares of Editas Medicine from a “sell” rating to a “hold” rating in a report on Wednesday, April 4th. Barclays upped their target price on shares of Editas Medicine from $28.00 to $46.00 and gave the stock an “overweight” rating in a report on Wednesday, March 7th. Cann reaffirmed a “hold” rating on shares of Editas Medicine in a report on Friday, February 16th. Finally, JMP Securities upped their target price on shares of Editas Medicine from $40.00 to $67.00 and gave the stock an “outperform” rating in a report on Wednesday, March 7th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and seven have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $46.14.

Editas Medicine Profile

Editas Medicine, Inc operates as a genome editing company. It focuses on treating patients with genetically defined diseases by correcting their disease causing genes. The company develops a proprietary genome editing platform based on CRISPR technology to target genetically defined diseases with an initial focus on debilitating illnesses where there are no approved treatments.

Institutional Ownership by Quarter for Editas Medicine (NASDAQ:EDIT)

Receive News & Ratings for Editas Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply